Golden
Visterra

Visterra

A company developing antibody-based biological medicines for kidney diseases and other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.

All edits

Edits on 15 Jun 2019
Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 15 Jun 2019 6:26 am
Edits made to:
Article (+11/-11 characters)

Article

On October 2, 2014 Visterra completed their series B funding round with $30 million in funding from Temasek Holdings (lead investor), Vertex ventures, Polaris Partners, Omega Funds, Merck Research Laboratories, Flagship Pioneering, Cycad GroupCycad Group, CTI Life Science Fund, and Alexandria Venture. 

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 15 Jun 2019 4:24 am
Edits made to:
Article (+11/-11 characters)

Article

On December 2, 2013 Visterra completed their series A funding round with $8.1 million in funding from the Bill & Melinda Gates Foundation and Omega FundsOmega Funds. 

Edits on 14 Jun 2019
Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 14 Jun 2019 2:28 pm
Edits made to:
Article (+15/-15 characters)

Article

On October 2, 2014 Visterra completed their series B funding round with $30 million in funding from Temasek Holdings (lead investor), Vertex venturesVertex ventures, Polaris Partners, Omega Funds, Merck Research Laboratories, Flagship Pioneering, Cycad Group, CTI Life Science Fund, and Alexandria Venture. 

Axel Fehr
Axel Fehr approved a suggestion from Golden's AI on 14 Jun 2019 1:38 pm
Edits made to:
Article (+23/-23 characters)

Article

On October 5, 2017 Visterra completed their series C founding round with $46.7 million in funding from the Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture HoldingsVertex Venture Holdings, Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture Investments, Serum Institute of India, CTI Life Sciences, and Allegheny Financial Group.

Edits on 12 Jun 2019
Golden AI
Golden AI edited on 12 Jun 2019 10:20 pm
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 31 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 31 Mar 2019 7:46 pm
Edits made to:
Article (+16/-16 characters)

Article

On October 2, 2014 Visterra completed their series B funding round with $30 million in funding from Temasek HoldingsTemasek Holdings (lead investor), Vertex ventures, Polaris Partners, Omega Funds, Merck Research Laboratories, Flagship Pioneering, Cycad Group, CTI Life Science Fund, and Alexandria Venture. 

Edits on 30 Mar 2019
Sarah Rioflorido
Sarah Rioflorido approved a suggestion from Golden's AI on 30 Mar 2019 12:29 pm
Edits made to:
Article (+24/-24 characters)

Article

Visterra is a biotechnology company headquartered in Cambridge, MassachusettsCambridge, Massachusetts and was founded in 2007 by Kevin Bitterman and Ram Sasisekharan. In mid-2018 Visterra was purchased by Otsuka Pharmaceutical Co. for $430 million. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 10:33 pm
Edits made to:
Article (+21/-21 characters)

Article

Visterra is a biotechnology company headquartered in Cambridge, Massachusetts and was founded in 2007 by Kevin Bitterman and Ram Sasisekharan. In mid-2018 Visterra was purchased by Otsuka PharmaceuticalOtsuka Pharmaceutical Co. for $430 million. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 10:33 pm
Edits made to:
Article (+31/-31 characters)

Article

On December 2, 2013 Visterra completed their series A funding round with $8.1 million in funding from the Bill & Melinda Gates FoundationBill & Melinda Gates Foundation and Omega Funds. 

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 6:46 pm
Edits made to:
Article (+5/-5 characters)

Article

On October 5, 2017 Visterra completed their series C founding round with $46.7 million in funding from the Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings, Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture Investments, Serum Institute of IndiaIndia, CTI Life Sciences, and Allegheny Financial Group.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 6:15 pm
Edits made to:
Article (+30/-30 characters)

Article

On October 5, 2017 Visterra completed their series C founding round with $46.7 million in funding from the Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings, Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture InvestmentsAlexandria Venture Investments, Serum Institute of India, CTI Life Sciences, and Allegheny Financial Group.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 29 Mar 2019 4:38 pm
Edits made to:
Article (+16/-16 characters)

Article

On May 10, 2009 Visterra completed their seed funding round with $3.3 million in funding from Polaris partnersPolaris partners, Lux Capital, and Flagship Pioneering. 

Edits on 29 Mar 2019
Dawson Sewell
Dawson Sewell edited on 29 Mar 2019 4:04 pm
Edits made to:
Infobox (+6/-1 properties)
Timeline (+4 events) (+1039 characters)
Article (+1218 characters)
Further reading (+4 cells) (+153 characters)
Related Topics (+1 topics)

Article

Visterra is a biotechnology company headquartered in Cambridge, Massachusetts and was founded in 2007 by Kevin Bitterman and Ram Sasisekharan. In mid-2018 Visterra was purchased by Otsuka Pharmaceutical Co. for $430 million. 



...

Funding

Seed

On May 10, 2009 Visterra completed their seed funding round with $3.3 million in funding from Polaris partners, Lux Capital, and Flagship Pioneering. 

Series A

On December 2, 2013 Visterra completed their series A funding round with $8.1 million in funding from the Bill & Melinda Gates Foundation and Omega Funds. 

Series B

On October 2, 2014 Visterra completed their series B funding round with $30 million in funding from Temasek Holdings (lead investor), Vertex ventures, Polaris Partners, Omega Funds, Merck Research Laboratories, Flagship Pioneering, Cycad Group, CTI Life Science Fund, and Alexandria Venture. 

Series C

On October 5, 2017 Visterra completed their series C founding round with $46.7 million in funding from the Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings, Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture Investments, Serum Institute of India, CTI Life Sciences, and Allegheny Financial Group.

Further reading

Title
Author
Link
Type

Otsuka Pharmaceutical to Acquire Visterra

Business Wire

Web

Infobox

Related Topics

Timeline

October 5, 2017

Series C funding round

On October 5, 2017 Visterra completed their series C founding round with $46.7 million in funding from the Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings, Polaris Partners, Flagship Pioneering, Omega Funds, Cycad Group, Alexandria Venture Investments, Serum Institute of India, CTI Life Sciences, and Allegheny Financial Group.

October 2, 2014

Series B funding round

On October 2, 2014 Visterra completed their series B funding round with $30 million in funding from Temasek Holdings (lead investor), Vertex ventures, Polaris Partners, Omega Funds, Merck Research Laboratories, Flagship Pioneering, Cycad Group, CTI Life Science Fund, and Alexandria Venture. 

December 2, 2013

Series A funding round

On December 2, 2013 Visterra completed their series A funding round with $8.1 million in funding from the Bill & Melinda Gates Foundation and Omega Funds. 

May 10, 2009

Seed funding round

On May 10, 2009 Visterra completed their seed funding round with $3.3 million in funding from Polaris partners, Lux Capital, and Flagship Pioneering. 

Edits on 20 Mar 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 20 Mar 2019 12:50 am
Edits made to:
Article (+19/-19 characters)

Article

Visterra initially worked on development of a line of therapeutics and vaccines for infectious diseases using technology based on the interaction between viruses and human cells using computational tools. One product candidate is a human monoclonal antibodymonoclonal antibody for seasonal and pandemic influenza. A human monoclonal antibody for dengue that neutralizes all four Dengue virus serotypes was also developed by Visterra. Their infectious disease programs are being advanced through partnerships.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar 2019 10:41 pm
Edits made to:
Article (+18/-18 characters)

Article

In 2018 Visterra announced the initiation of a human phase 1, randomized, placebo-controlled, double-blind, single ascending dose study to assess the safety of VIS649 in healthy subjects. VIS649 is an IgG2 monoclonal antibody designed with their Hierotope platform to target cytokine APRIL (A Proliferation Inducing Ligand) and neutralize activity as a potential treatment for IgA nephropathy. IgA nephropathy is a chronic, progressive autoimmune diseaseautoimmune disease where IgA immune complexes form deposits in the kidneys causing kidney inflammation, hematuria, proteinuria and progressive damage to the kidney. As of 2018 there were no approved therapies for this disease.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:15 pm
Edits made to:
Article (+15/-15 characters)

Article

In 2018 Visterra announced the initiation of a human phase 1, randomized, placebo-controlled, double-blind, single ascending dose study to assess the safety of VIS649 in healthy subjects. VIS649 is an IgG2 monoclonal antibody designed with their Hierotope platform to target cytokine APRIL (A Proliferation Inducing Ligand) and neutralize activity as a potential treatment for IgA nephropathyIgA nephropathy. IgA nephropathy is a chronic, progressive autoimmune disease where IgA immune complexes form deposits in the kidneys causing kidney inflammation, hematuria, proteinuria and progressive damage to the kidney. As of 2018 there were no approved therapies for this disease.

Jude Gomila
Jude Gomila approved a suggestion from Golden's AI on 19 Mar 2019 6:11 pm
Edits made to:
Article (+12/-12 characters)

Article

Visterra initially worked on development of a line of therapeutics and vaccines for infectious diseases using technology based on the interaction between viruses and human cells using computational tools. One product candidate is a human monoclonal antibody for seasonal and pandemic influenza. A human monoclonal antibody for dengue that neutralizes all four Dengue virusDengue virus serotypes was also developed by Visterra. Their infectious disease programs are being advanced through partnerships.

Edits on 18 Mar 2019
Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 3:02 am
Edits made to:
Article (+664/-3 characters)

Article

In 2018 Visterra announced the initiation of a human phase 1, randomized, placebo-controlled, double-blind, single ascending dose study to assess the safety of VIS649 in healthy subjects. VIS649 is an IgG2 monoclonal antibody designed with their Hierotope platform to target cytokine APRIL (A Proliferation Inducing Ligand) and neutralize activity as a potential treatment for IgA nephropathy. IgA nephropathy is a chronic, progressive autoimmune disease where IgA immune complexes form deposits in the kidneys causing kidney inflammation, hematuria, proteinuria and progressive damage to the kidney. As of 2018 there were no approved therapies for this disease.



Visterra’s Hierotope Platform areis used to design and engineer antibodies to target specific epitopes, which are regions of the disease target made up of highly networked amino acids which they call hierotopes. The Hierotop Platform uses their Atomic Interaction Network (AIN) Analysis to characterise amino acids in the protein of a selected disease target to identify the most highly networked or interconnected. DropPair Technology is used to generate and screen millions of natively paired antibodies based on binding and affinity to a disease target and other key functions and characteristics. This allows selection of lead candidates.

Meredith Hanel
Meredith Hanel edited on 18 Mar 2019 2:18 am
Edits made to:
Description (+88/-11 characters)
Article (+1227 characters)
People (+20 cells) (+438 characters)
Categories (+1/-2 topics)
Topic thumbnail

Visterra

A company developing antibody-based biological medicines for hardkidney todiseases treatand other chronic diseases. Visterra was acquired by Otsuka Pharmaceutical in 2018.

Article

Visterra initially worked on development of a line of therapeutics and vaccines for infectious diseases using technology based on the interaction between viruses and human cells using computational tools. One product candidate is a human monoclonal antibody for seasonal and pandemic influenza. A human monoclonal antibody for dengue that neutralizes all four Dengue virus serotypes was also developed by Visterra. Their infectious disease programs are being advanced through partnerships.



Visterra’s Hierotope Platform are used to design and engineer antibodies to target specific epitopes, which are regions of the disease target made up of highly networked amino acids which they call hierotopes. The Hierotop Platform uses their Atomic Interaction Network (AIN) Analysis to characterise amino acids in the protein of a selected disease target to identify the most highly networked or interconnected. DropPair Technology is used to generate and screen millions of natively paired antibodies based on binding and affinity to a disease target and other key functions and characteristics. This allows selection of lead candidates.



Visterra is licensed from MIT and based on scientific work in Dr. Ram Sasisekharan’s laboratory. 

People

Name
Role
Related Golden topics

Alan Crane

Founder



Brian J. G. Pereira, MD

President, CEO



Chris Kiefer

Chief Administrative Officer, General Counsel and Corporate Secretary



David Oldach, MD, FIDSA

Chief Medical Officer



Greg Babcock, PhD.

Vice President, Research



Greg Miller

Chief Business Officer



Jean L. Bender

Vice President, Pharmaceutical Sciences and Technology



Ram Sasisekharan

Founder



Todd Curtis

Vice President, Finance and Controller



Zachary Shriver, PhD

Chief Scientific Officer



Categories

Edits on 21 Jan 2019
Golden AI"Changed markets to industries"
Golden AI edited on 21 Jan 2019 10:16 pm
Edits made to:
Infobox (+1/-1 properties)

Infobox